MCM
EIGR

Manchester Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Manchester Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-30
Closed -$263K – 926
2014
Q4 		$263K Hold
30
– – 0.03% 297
2014
Q3 		$141K Buy
+30
New +$159K 0.02% 465

Other funds holding EIGR

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Manchester Capital Management's EIGR Position: Q1 2015 in Review

Manchester Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2015, closing a stake of 30 shares — an estimated $263K sold.

Manchester Capital Management first reported a position in EIGR in Q3 2014 and held it in 2 quarters. The position peaked at $263K in Q4 2014. 84 funds tracked by Wall St. Rank hold EIGR as of Q1 2015.

  • Manchester Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Manchester Capital Management sold 30 Eiger BioPharmaceuticals, Inc. shares in Q1 2015, an estimated $263K.
  • Manchester Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2014 and held it in 2 quarters.
  • Manchester Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $263K in Q4 2014.
  • 84 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2015.

Based on Manchester Capital Management's 13F filing for Q1 2015, filed 7 May 2015.